ReviewFrontiers in immunology2026
PD-1 blockade combined with anlotinib and bicalutamide for metastatic primary cutaneous apocrine carcinoma: a case report and literature review.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary cutaneous apocrine carcinoma (PCAC) is a rare malignant adnexal tumor with substantial diagnostic complexity and no established systemic therapy standard for advanced disease.Evidence for endocrine therapy, targeted therapy, and immune checkpoint inhibitors is limited to small series and case reports. Case presentation: A patient presented with a pruritic erythematous plaque on the left chest wall that progressively enlarged over one year. Skin biopsy and subsequent pathology consultation demonstrated invasive adenocarcinoma involving the dermis and subcutaneous tissue. Immunohistochemistry supported PCAC (CK7+, GATA3+, AR strongly positive, and patchy GCDFP-15 positivity), and a left axillary lymph node confirmed metastatic carcinoma. Whole-body Conclusion: This case illustrates a feasible combination approach for widely metastatic PCAC using PD-1 blockade, anti-angiogenic therapy, and anti-androgen treatment, with clinical and radiographic improvement and favorable tolerability during follow-up. Prospective data are needed to clarify patient selection and define optimal systemic strategies for advanced PCAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.